These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 3690537)

  • 21. Pure-type clear cell carcinoma of the ovary as a distinct histological type and improved survival in patients treated with paclitaxel-platinum-based chemotherapy in pure-type advanced disease.
    Ho CM; Huang YJ; Chen TC; Huang SH; Liu FS; Chang Chien CC; Yu MH; Mao TL; Wang TY; Hsieh CY
    Gynecol Oncol; 2004 Jul; 94(1):197-203. PubMed ID: 15262142
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Six-drug chemotherapy (hexamethylmelamine, doxorubicin, cisplatin, cyclophosphamide, methotrexate, and 5-FU; CHAMP-5) for ovarian carcinoma: alternating sequences of combination regimens.
    Pasmantier MW; Coleman M; Silver RT; Ballard WP
    Cancer Treat Rep; 1985 Jun; 69(6):689-93. PubMed ID: 3926310
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Chemotherapy of epithelial ovarian carcinoma].
    Bruntsch U; Gallmeier WM
    MMW Munch Med Wochenschr; 1983 Nov; 125(44):993-5. PubMed ID: 6417517
    [No Abstract]   [Full Text] [Related]  

  • 24. [Comparative research on different treatment regimens in disseminated cancer of the ovaries].
    Marinov L; Koĭnov K; Tsekova V; Velikova M
    Akush Ginekol (Sofiia); 1987; 26(1):49-52. PubMed ID: 3592111
    [No Abstract]   [Full Text] [Related]  

  • 25. [Complete remission of recurrent ovarian dysgerminoma obtained by combined chemotherapy with cisplatin, adriamycin and cyclophosphamide].
    Yokota H; Saito M; Tsunoda H; Kawagoe K
    Gan To Kagaku Ryoho; 1985 Jan; 12(1):151-4. PubMed ID: 4038447
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Importance of anthracyclines in tumors of the ovary and endometrium and soft tissue sarcomas].
    Mignot L
    Pathol Biol (Paris); 1987 Jan; 35(1):118-22. PubMed ID: 3550606
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Combined modality for recurrent and disseminated ovarian cancer--CAPF combination chemotherapy and second-look operation].
    Inagaki J; Ogawa M; Horikoshi N; Ezaki K; Inoue K; Aiba K; Komyo M; Miyamoto H; Ikeda K; Kubo H
    Gan No Rinsho; 1983 Aug; 29(10):1291-5. PubMed ID: 6685195
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Improved therapy with cisplatin regimens for patients with ovarian carcinoma (FIGO III and IV) as measured by surgical end-staging (second-look surgery)--the mount sinai experience.
    Cohen CJ; Bruckner HW; Goldberg JD; Holland JF
    Clin Obstet Gynaecol; 1983 Aug; 10(2):307-24. PubMed ID: 6413114
    [No Abstract]   [Full Text] [Related]  

  • 29. Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials.
    Thigpen T; Vance R; Puneky L; Khansur T
    Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S97-107. PubMed ID: 7835816
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Adjuvant chemotherapy in dysgerminoma].
    Fechtig A; de Dycker RP; Schumacher T; Neumann RL
    Geburtshilfe Frauenheilkd; 1991 May; 51(5):398-400. PubMed ID: 1869011
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The second look at tumors of the ovary. Our experience].
    Sanlorenzo M; Vigezzi P; Caldarola F; Allone T
    Minerva Chir; 1988 Sep; 43(18):1477-9. PubMed ID: 2465506
    [No Abstract]   [Full Text] [Related]  

  • 32. Hexamethylmelamine-CAF (cyclophosphamide, methotrexate, and 5-FU) and cisplatin-CAF in refractory ovarian cancer.
    Sessa C; D'Incalci M; Valente I; Bolis G; Colombo N; Mangioni C
    Cancer Treat Rep; 1982 May; 66(5):1233-4. PubMed ID: 6805951
    [No Abstract]   [Full Text] [Related]  

  • 33. [Intraperitoneal high dose chemotherapy as consolidation treatment for advanced ovarian carcinoma: a pilot study].
    Gladieff L; Chatelut E; Gaspard MH; Skaf R; de Forni M; Mihura J; Canal P; Bugat R
    Bull Cancer; 1999; 86(7-8):673-7. PubMed ID: 10477384
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Clinical study of combination chemotherapy with CDDP, ADM and CPM for ovarian cancer].
    Kobayashi H; Maeda M; Hayata T; Kawashima Y
    Nihon Gan Chiryo Gakkai Shi; 1988 Apr; 23(4):829-36. PubMed ID: 3204307
    [No Abstract]   [Full Text] [Related]  

  • 35. Response of ovarian cancer to combined cytotoxic agents in the subrenal capsule assay: Part I.
    Mäenpää J; Kangas L; Grönroos M
    Obstet Gynecol; 1985 Nov; 66(5):708-13. PubMed ID: 3932908
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A pilot study of cisplatin, ifosfamide and mesna in the treatment of malignant mixed mesodermal tumors of the ovary.
    Crotzer DR; Wolf JK; Gano JB; Gershenson DM; Levenback C
    Gynecol Oncol; 2007 May; 105(2):399-403. PubMed ID: 17292457
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cisplatin, epirubicin, and ifosfamide versus cisplatin, epirubicin, and cyclophosphamide in clear cell carcinoma of the ovary.
    Nishida T; Sugiyama T; Yakushiji M
    Gynecol Oncol; 1997 Nov; 67(2):230. PubMed ID: 9367714
    [No Abstract]   [Full Text] [Related]  

  • 38. Short-term effects of chemotherapy-surgery-chemotherapy regimen on clinically inoperable advanced ovarian cancer.
    Feng Y; Sun T
    Chin Med J (Engl); 1998 Aug; 111(8):722-5. PubMed ID: 11245027
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Chemotherapeutic treatment of advanced ovarian carcinoma. Preliminary results of the Piedmont-Liguria Cooperative Group].
    Conte PF; Rosso R; Bruzzone M; Sertoli MR; Rubagotti A; Santi L; Carnino F; Cottini M; Mossetti C; Gatti M
    Minerva Ginecol; 1984 Apr; 36(4):213-6. PubMed ID: 6547773
    [No Abstract]   [Full Text] [Related]  

  • 40. High-dose chemotherapy with autologous bone marrow transplantation for the treatment of malignant ovarian tumors.
    Murakami M; Shinozuka T; Kuroshima Y; Tokuda Y; Tajima T
    Semin Oncol; 1994 Feb; 21(1 Suppl 1):29-32. PubMed ID: 8153654
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.